Page last updated: 2024-10-28

ifenprodil and Mental Disorders

ifenprodil has been researched along with Mental Disorders in 1 studies

ifenprodil: NMDA receptor antagonist

Mental Disorders: Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hashimoto, K1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia (FluCOP Trial)[NCT05216614]Phase 20 participants (Actual)Interventional2021-12-14Withdrawn (stopped due to Unable to obtain investigational product)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for ifenprodil and Mental Disorders

ArticleYear
Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication.
    Journal of pharmacological sciences, 2015, Volume: 127, Issue:1

    Topics: Animals; Donepezil; Humans; Indans; Mental Disorders; Models, Neurological; Neurotransmitter Agents;

2015